|
Market Closed -
Nasdaq
01:30:00 05/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 59.01 USD | -0.20% |
|
+8.37% | +34.63% |
| 01/09 | Exelixis Wins Appeal in Patent Case Against MSN Laboratories | MT |
| 06/08 | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.47TCr | |||||
| 6.9TCr | |||||
| 6.63TCr | |||||
| 2.77TCr | - | ||||
| 2.65TCr | |||||
| 2.58TCr | - |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
